Title of article
Inhibitors of unactivated p38 MAP kinase
Author/Authors
James Bullington، نويسنده , , Dennis Argentieri، نويسنده , , Kristin Averill، نويسنده , , Demetrius Carter، نويسنده , , Druie Cavender، نويسنده , , Bohumila Fahmy، نويسنده , , Xiaodong Fan، نويسنده , , Daniel Hall، نويسنده , , Geoffrey Heintzelman، نويسنده , , Paul Jackson، نويسنده , , Wai-Ping Leung، نويسنده , , Xun Li، نويسنده , , Ping Ling، نويسنده , , Gilbert Olini، نويسنده , , Thomas Razler، نويسنده , , Michael Reuman، نويسنده , , Kenneth Rupert، نويسنده , , Ronald Russell، نويسنده , , John Siekierka، نويسنده , , Scott Wadsworth، نويسنده , , et al.، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2006
Pages
5
From page
6102
To page
6106
Abstract
Inhibition of the p38 map kinase pathway has been shown to be beneficial in the treatment of inflammatory diseases. The first class of potent p38 kinase inhibitors was the pyridinylimidazole compounds from SKB. Since then several pyridinylimidazole-based compounds have been shown to inhibit activated p38 kinase in vitro and in vivo. We have developed a novel series of pyridinylimidazole-based compounds, which potently inhibit the p38 pathway by binding to unactivated p38 kinase and only weakly inhibiting activated p38 kinase activity in vitro.
Keywords
kinase , pyrrole , toxicity , P38 , TNF
Journal title
Bioorganic & Medicinal Chemistry Letters
Serial Year
2006
Journal title
Bioorganic & Medicinal Chemistry Letters
Record number
797536
Link To Document